Exane Derivatives’s TechnipFMC FTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,075
Closed -$1M 846
2020
Q3
$1M Hold
1,075
0.29% 82
2020
Q2
$904K Sell
1,075
-1,371
-56% -$7.99K 0.24% 91
2020
Q1
$2.64M Sell
2,446
-5,579
-70% -$61.2K 0.74% 33
2019
Q4
$711K Buy
8,025
+3,459
+76% +$53.7K 0.13% 123
2019
Q3
$561K Buy
4,566
+138
+3% +$2.57K 0.1% 156
2019
Q2
$624K Sell
4,428
-632
-12% -$11.1K 0.11% 149
2019
Q1
$932K Buy
5,060
+1,028
+25% +$17.4K 0.18% 123
2018
Q4
$1.69M Sell
4,032
-449
-10% -$8.35K 0.3% 85
2018
Q3
$599K Buy
4,481
+418
+10% +$9.48K 0.11% 150
2018
Q2
$657K Sell
4,063
-7,653
-65% -$182K 0.11% 156
2018
Q1
$1.68M Buy
11,716
+2,243
+24% +$51.9K 0.34% 80
2017
Q4
$833K Sell
9,473
-3,174
-25% -$65.7K 0.14% 115
2017
Q3
$1.5M Buy
12,647
+7,256
+135% +$146K 0.28% 69
2017
Q2
$1.27M Sell
5,391
-8,226
-60% -$185K 0.27% 87
2017
Q1
$437K Buy
+13,617
New +$336K 0.1% 140

Other funds holding FTI

Exane Derivatives's FTI Position: Q2 2022 in Review

Exane Derivatives opened a new position in TechnipFMC (FTI) in Q2 2022: 65,500 shares worth $441K. The stake represents 0.25% of the portfolio and ranks #100 among its holdings. This is a return to the name: Exane Derivatives previously reported a position in FTI as recently as Q4 2021.

Exane Derivatives first reported a position in FTI in Q1 2017 and has held it in 20 quarters since. The position peaked at $13.7M in Q3 2017. 252 funds tracked by Wall St. Rank hold FTI as of Q2 2022.

  • Exane Derivatives held 65,500 shares of TechnipFMC worth $441K as of Q2 2022.
  • TechnipFMC was a new Exane Derivatives position in Q2 2022.
  • TechnipFMC made up 0.25% of Exane Derivatives's portfolio in Q2 2022, its #100 holding.
  • Exane Derivatives first reported a position in TechnipFMC in Q1 2017 and has held it in 20 quarters since.
  • Exane Derivatives's TechnipFMC position peaked at $13.7M in Q3 2017.
  • 252 funds tracked by Wall St. Rank held TechnipFMC as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.